Gsk (GSK) Receivables Refunds (2009 - 2026)

Gsk (GSK) has 10 years of Receivables Refunds data on file, last reported at $383.1 million in Q4 2025.

• In Q4 2025, Receivables Refunds fell 38.96% year-over-year to $383.1 million; the TTM figure through Dec 2025 stood at $383.1 million (down 38.96% YoY), while the FY2025 annual figure was $383.1 million, down 38.96% from the prior year.
• Receivables Refunds declined to $383.1 million in Q4 2025, from $627.6 million in the prior quarter.
• Across five years, Receivables Refunds topped out at $655.1 million in Q4 2021 and bottomed at $383.1 million in Q4 2025.
• A 5-year average of $520.8 million and a median of $475.0 million in 2022 frame the typical range for Receivables Refunds.
• Annual changes were most pronounced in 2024 — Receivables Refunds soared 35.57% — and 2025, when it tumbled 38.96%.
• Year by year, Receivables Refunds stood at $655.1 million in 2021, then dropped by 27.49% to $475.0 million in 2022, then fell by 2.54% to $462.9 million in 2023, then soared by 35.57% to $627.6 million in 2024, then tumbled by 38.96% to $383.1 million in 2025.
• The last three Receivables Refunds figures came in at $383.1 million (Q4 2025), $627.6 million (Q4 2024), and $462.9 million (Q4 2023), per Business Quant data.

Peer Comparison